When a treatment team is in another country, small differences in the diagnosis, proposed procedure, and follow-up plan matter more. You need to know what the clinic intends to treat, what evidence supports that choice, and who will help if you become unwell after returning home.

That scrutiny is especially important for stem cell therapy for celiac disease abroad. A strict gluten-free diet remains the standard treatment for celiac disease. Stem cell treatment is not established for routine celiac disease, and the term can describe procedures with very different risks.

Confirm which celiac-related condition the overseas team intends to treat

Persistent symptoms do not, by themselves, mean that celiac disease is refractory. Gluten exposure, another intestinal condition, or an incorrect original diagnosis may explain why you still feel ill. A specialist should review the original diagnosis, a dietitian’s assessment of your gluten-free diet, blood tests, and repeat small-intestine biopsies before proposing a transplant.

The distinction between the following diagnoses changes both the treatment and the level of risk that might be justified.

Biopsy reports may also describe the extent of intestinal damage using a Marsh classification. That grade is useful, but it cannot establish RCD-II on its own. The team must interpret it alongside symptoms, diet review, and tests of the intestinal lymphocytes.

What to confirm about your diagnosis

Ask the overseas clinic to state its working diagnosis and the evidence for it in writing. If it suspects RCD-II, ask whether a specialist pathologist will review your biopsy samples and how abnormal lymphocytes will be assessed. If lymphoma is suspected, ask who will establish or exclude that diagnosis before any transplant decision.

Check why transplantation is being proposed instead of another option

For most people with celiac disease, the practical next step is not a stem cell procedure. It is a careful search for ongoing gluten exposure, nutritional deficiencies, and other causes of symptoms, followed by treatment directed at what is found. RCD-I and RCD-II need specialist management, but they do not automatically call for transplantation.

Depending on the diagnosis, alternatives may include supervised dietary work, nutritional support, medicines selected by a refractory-celiac specialist, or lymphoma treatment planned by an oncology team. Medicines sometimes used in refractory disease, including corticosteroid-based treatment, require individual assessment. The same specialist review or treatment may also be available closer to home, where coordination with your usual doctors can be easier.

For severe RCD-II, a proposed autologous transplant uses your own blood-forming stem cells. Its aim is to replace blood and immune cells after intensive conditioning treatment. It does not directly repair the intestine or remove the need for a gluten-free diet. If a proposal instead offers donated cells, laboratory-grown cells, or a simple infusion, ask why that approach is appropriate for your exact diagnosis and what evidence supports it.

What to confirm about the decision

Ask: “What has been ruled out, what treatments have I already tried, and what makes this option preferable to continued specialist care or treatment at home?” A useful answer should address your biopsy findings, nutritional state, previous treatment response, and personal transplant risks. An offer that promises to cure all forms of celiac disease without making these distinctions needs clarification.

Understand the proposed stem cell procedure before comparing clinics

A transplant is a multistage medical treatment, not a single stem cell injection. The sequence below describes the general pathway for an autologous blood stem cell transplant. Your written plan should explain every stage the team actually proposes.

1. Confirm eligibility. A gastroenterologist and transplant team review the diagnosis, organ function, infections, nutrition, previous treatment, and fitness for intensive care.
2. Collect stem cells. Treatment moves blood-forming cells into the bloodstream. A collection machine then separates and stores them. Ask how the collected cells will be tested and preserved.
3. Give conditioning treatment. Intensive medicines prepare the body for the transplant. This is a major source of short-term risk and requires close monitoring.
4. Infuse the stored cells. The cells are returned through a vein. The infusion itself is only one part of the treatment.
5. Support blood-count recovery. The team monitors for infection, bleeding, and other complications while the transplanted cells begin making new blood cells.

Techniques and product names can differ between programs. Ask for the cell source, whether cells are your own or a donor’s, the collection and processing method, the conditioning regimen, and the planned supportive medicines. Where a particular product, processing system, or medicine brand matters to the proposal, request its name in writing rather than assuming two plans use equivalent materials.

A clinic should also explain whether its proposal is established transplant care for another diagnosis, an investigational approach for RCD-II, or participation in a formal clinical study. These are different situations with different consent, oversight, and follow-up requirements.

What to confirm about the people and facility

Ask who makes the diagnosis, who leads the transplant, and who is present during conditioning and early recovery. Verify that the facility is licensed for the proposed transplant work and can provide cell collection and storage, specialist pathology, blood-product support, infection treatment, and urgent hospital care. Ask how many patients with your particular diagnosis the team has assessed or treated, rather than relying on its experience with unrelated stem cell procedures.

Send records from home, then expect a second assessment in person

A remote review can establish whether a specialist consultation makes sense. It cannot guarantee that transplantation will proceed. The overseas team may change its recommendation after examining you, reviewing original biopsy material, or repeating tests.

Before booking, ask which of these records it needs:

• Diagnosis: original celiac blood tests, endoscopy and biopsy reports, pathology slides if available, and later biopsy findings.
• Refractory-disease work-up: dietitian assessment, lymphocyte testing, relevant imaging, and reports addressing possible lymphoma.
• General health: blood counts, nutritional tests, infection history, heart and lung assessments if performed, and details of other conditions.
• Treatment history: medicines and supplements, allergies, previous therapies and responses, and contact details for your treating specialists.

Fitness matters as much as the biopsy result. Older age alone may not settle eligibility, but frailty, active infection, significant organ disease, poorly controlled diabetes, smoking, and complications associated with a high body mass index can increase treatment risk. The transplant team should assess these factors individually. Do not stop or change medicines on your own before travelling.

Preparation often begins at home with nutrition support, review of infections and vaccinations, and a plan for managing existing conditions. Ask your local gastroenterologist whether they can help obtain records and remain involved. That conversation is especially valuable if the overseas assessment leads to a different diagnosis or no transplant.

Terms worth recognizing in your records

Put transplant risks and realistic goals in the same conversation

Conditioning can cause severe infection while blood counts are low, bleeding, mouth or digestive-tract injury, organ complications, and treatment-related death. Collection and infusion have their own possible complications. Teams reduce risk through eligibility checks, protective monitoring, infection treatment, transfusion support, and rapid access to hospital care, but they cannot remove it.

Published complication rates from other transplant groups are not reliable estimates for an individual with rare RCD-II. Even a percentage from a small RCD-II series may change substantially with patient selection and transplant method. Ask the team for the range it considers applicable to you, its own complication and treatment-related mortality data where available, and an explanation of where evidence is too limited to give a sound estimate.

Results also need careful language. Small specialist reports suggest that some selected RCD-II patients may improve after autologous transplantation, but there is no dependable success percentage or guaranteed duration of benefit that applies across patients. Improvement might mean fewer symptoms, better nutrition, less intestinal damage, or a change in abnormal lymphocytes. These are not interchangeable measures of success.

RCD-II can relapse or progress to lymphoma, so improvement does not end surveillance. For EATL, ask the oncology team to discuss expected cancer outcomes separately. If an overseas offer claims a permanent celiac cure or quotes a success rate without defining the diagnosis and outcome measured, request the underlying evidence.

What to confirm about risk and benefit

Ask: “What result would make this treatment worthwhile in my case, how will you measure it, and when will you reassess?” Then ask who provides emergency care during recovery, what the clinic can address remotely after discharge, and which problems must be treated immediately by a local hospital.

Plan for recovery with the treating team and your doctor at home

Recovery is a body timeline, not just a discharge date. During collection and conditioning, you need access to the transplant team. After infusion, low blood counts and infection risk generally require the closest observation. Blood-count recovery is an important milestone, but it does not mean your immune system or strength has fully recovered.

Later, fatigue, nutritional needs, medication review, and monitoring for returning intestinal disease may continue at home. The treating team should say what clinical and laboratory findings must be stable before you leave its direct care. Travel plans should follow that assessment, not the date on an initial itinerary. A companion may be helpful if you are weak or need support with appointments and instructions.

Before returning home, obtain a discharge summary, the collection and transplant record, details of conditioning and cell processing, test results, prescriptions, infection precautions, and emergency contact information. Ask for a written schedule for blood tests, gastroenterology review, and any repeat intestinal assessments. Your local doctor should receive the same plan and know which overseas clinician will answer questions.

Seek urgent local medical care for fever, shaking chills, new breathlessness, uncontrolled bleeding, severe diarrhea, dehydration, confusion, or rapidly worsening weakness. Do not wait for a remote reply if you may be seriously ill. Establish before departure which local hospital can assess you and whether the overseas team will promptly supply records to its clinicians.

Long-term care may include continued gluten avoidance, nutritional treatment, biopsy-based assessment, and monitoring for lymphoma when indicated. If disease returns or a later complication requires another procedure, your local specialists and the original team should review the findings together. Another trip might be considered, but it should not be assumed to be the only route to treatment.

Compare overseas proposals by clinical fit, not the headline quote

There is no dependable standard international price for stem cell treatment of RCD-II. A transplant assessment, intensive hospital treatment, cell collection and processing, and complication care are not equivalent to a quoted price for an infusion. The final cost can change with the diagnosis, conditioning plan, specialist and facility fees, tests, medicines, hospital care, and rehabilitation needs. Treatment charges and total travel expenses are separate.

Destination comparisons should start with the availability of a genuine celiac and transplant multidisciplinary team, regulatory oversight, specialist pathology, supportive hospital care, and a workable handover to your doctor at home. Access or waiting time may matter, but neither makes an investigational intervention appropriate on its own. A PlacidWay patient coordinator can help with destination options, itemized prices, and travel logistics.

Request these points in writing from each provider so that you can compare like with like:

A credible proposal identifies the treating clinicians and facility, gives a reasoned diagnosis and treatment plan, describes major risks and expected recovery, and sets out inclusions and exclusions. It also acknowledges uncertainty. The cheapest offer is not the best clinical fit if essential assessment, hospital support, or cross-border follow-up is missing.

Discuss a specialist assessment for celiac disease abroad

If you are comparing care for suspected refractory celiac disease, speak with a patient coordinator about obtaining a clear specialist proposal before making a treatment commitment.

Request information

References

• National Institute of Diabetes and Digestive and Kidney Diseases — Celiac Disease
• National Institute of Diabetes and Digestive and Kidney Diseases — Diagnosis of Celiac Disease
• National Institute of Diabetes and Digestive and Kidney Diseases — Treatment for Celiac Disease
• National Cancer Institute — Stem Cell Transplants in Cancer Treatment
• U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products, Including Stem Cells and Exosomes

This page is for general information and is not medical advice. Consult a qualified gastroenterologist and transplant specialist about your diagnosis, treatment options, and personal risks.